Physician profile
Daniel Dansdill
NPI 1013449024
$9,175.04
in general payments reported to CMS, 2019-2025
17 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,610 · 2020: $110 · 2021: $774 · 2022: $1,250 · 2023: $1,920 · 2024: $1,486 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,430.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,059.22 | 2019-2025 | Hydrus Microstent, Rocklatan, Voyager Dslt |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,378.98 | 2019 | |
| Abbvie INC. | $1,310.48 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Sight Sciences, INC. | $1,094.39 | 2021-2024 | Omni Surgical System |
| Glaukos Corporation | $703.95 | 2023-2025 | Idosetr, Idose |
| Bausch & Lomb Americas INC. | $320.63 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| New World Medical,INC. | $271.20 | 2021-2025 | Clearpath, Streamline, Via360 |
| Allergan, INC. | $265.58 | 2021-2022 | |
| Nova Eye, INC. | $231.96 | 2024 | |
| Dompe US, INC. | $156.10 | 2021-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $86.42 | 2021 | |
| Thea Pharma INC. | $83.96 | 2022-2025 | Iyuzeh |
| Amgen INC. | $68.58 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $36.79 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $36.08 | 2021-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $35.42 | 2024 | |
| Ocular Therapeutix, INC. | $35.30 | 2024-2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dansdill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.